AbbVie Inc. (NYSE:ABBV) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of AbbVie Inc. (NYSE:ABBV) have earned an average rating of “Moderate Buy” from the twenty-five analysts that are covering the firm, Marketbeat reports. Six research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have assigned a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $252.9048.

ABBV has been the subject of a number of recent research reports. Bank of America upgraded shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price objective for the company in a research note on Thursday, April 30th. Barclays initiated coverage on shares of AbbVie in a research note on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price objective for the company. Guggenheim reiterated a “buy” rating and issued a $249.00 price objective on shares of AbbVie in a research note on Friday, May 1st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $240.00 price objective on shares of AbbVie in a research note on Thursday, April 30th. Finally, William Blair reiterated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th.

AbbVie Stock Down 0.7%

Shares of ABBV stock opened at $201.24 on Friday. The company has a 50 day moving average of $213.18 and a 200-day moving average of $221.00. The firm has a market cap of $355.83 billion, a P/E ratio of 99.13, a PEG ratio of 0.70 and a beta of 0.32. AbbVie has a 12-month low of $176.57 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 911.57%. The business had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same period in the previous year, the business earned $2.46 EPS. AbbVie’s revenue was up 12.4% compared to the same quarter last year. As a group, equities analysts expect that AbbVie will post 14.3 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date is Wednesday, April 15th. AbbVie’s payout ratio is currently 340.89%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie continued to draw bullish attention after reporting strong first-quarter results, with revenue and earnings coming in ahead of expectations and showing that growth is extending beyond Humira into newer drugs like Skyrizi and Rinvoq. AbbVie Delivers Strong Q1 Earnings Beyond Humira. This Dividend King Still Shines.
• Positive Sentiment: AbbVie completed an early safety study for ABBV-142, which may improve investor confidence in the company’s pipeline and future oncology growth prospects. AbbVie Completes Early Safety Study for ABBV-142, Nudging Pipeline Hopes Higher
• Positive Sentiment: AbbVie and adMare BioInnovations named RIME Therapeutics as a Biotech Innovators Award winner, reinforcing AbbVie’s efforts to support early-stage biotech innovation and build optionality around its pipeline ecosystem. AbbVie (ABBV), adMare BioInnovations Name RIME Therapeutics as Biotech Innovators Award Winner
• Positive Sentiment: Skyrizi ranked ahead of J&J’s Tremfya in April drug ad spending, signaling continued competitive momentum and heavy marketing support for one of AbbVie’s key growth brands. AbbVie’s Skyrizi beats out J&J’s Tremfya in April drug ad spending leaderboard
• Neutral Sentiment: Analyst commentary and Q1 earnings-call recaps highlighted ongoing interest in AbbVie’s post-Humira growth strategy, but these pieces were mostly interpretive rather than new market-moving disclosures. 5 must-read analyst questions from AbbVie’s Q1 earnings call
• Neutral Sentiment: Coverage on SKYRIZI expansion and reimbursement progress in Canada suggests continued international adoption, but the article framed these as part of an already constructive longer-term thesis rather than a single new catalyst. Does Strong Q1 Results And SKYRIZI Expansion Reshape The Bull Case For AbbVie (ABBV)?
• Negative Sentiment: One relative headwind is that ABBV shares have recently traded below key moving averages, reflecting some investor caution even as fundamentals remain solid.

Insiders Place Their Bets

In other news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.06% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Oslo Pensjonsforsikring AS purchased a new position in shares of AbbVie during the 1st quarter valued at $1,330,000. HORAN Wealth LLC grew its position in shares of AbbVie by 1.7% during the 1st quarter. HORAN Wealth LLC now owns 25,081 shares of the company’s stock valued at $5,505,000 after purchasing an additional 414 shares in the last quarter. Baader Bank Aktiengesellschaft grew its position in shares of AbbVie by 560.7% during the 1st quarter. Baader Bank Aktiengesellschaft now owns 7,380 shares of the company’s stock valued at $1,588,000 after purchasing an additional 6,263 shares in the last quarter. Andra AP fonden grew its position in shares of AbbVie by 44.2% during the 1st quarter. Andra AP fonden now owns 283,811 shares of the company’s stock valued at $61,726,000 after purchasing an additional 86,969 shares in the last quarter. Finally, Glenview Trust Co grew its position in shares of AbbVie by 1.4% during the 1st quarter. Glenview Trust Co now owns 421,257 shares of the company’s stock valued at $91,619,000 after purchasing an additional 5,930 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.